PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Highlights<br />
Key Questions Answered<br />
From a clinical st<strong>and</strong>point, there is a dem<strong>and</strong> for novel medical therapies that target <strong>and</strong><br />
relieve the symp<strong>to</strong>ms of PAD in IC <strong>and</strong> CLI patients. KOLs interviewed by <strong>Global</strong>Data<br />
expressed a desire for secondgeneration drug treatments that display superior efficacy <strong>and</strong><br />
favorable safety profiles compared <strong>to</strong> existing pharmacological. Environmental unmet needs<br />
for this particular indication include physician education, patient awareness, greater<br />
screening, <strong>and</strong> improved guidelines. What other unmet needs exist in this market? Will the<br />
drugs under development fulfil the unmet needs of the PAD market?<br />
The current latestage PAD pipeline encompasses AstraZenecas Brillinta, Bayer/Janssens<br />
Xarel<strong>to</strong> <strong>and</strong> Mercks Zontivity. Will the latestage drugs make a significant impact on the<br />
PAD market? Which of these drugs will have the highest peak sales at the highest CAGR,<br />
<strong>and</strong> why?<br />
Key Findings<br />
The major drivers of this expansion in the PAD market will be the advent of novel<br />
antithrombotic agents, such as Brilinta <strong>and</strong> Xarel<strong>to</strong>, on<strong>to</strong> the PAD stage, <strong>and</strong> the increasing<br />
prevalence of PAD across all of the 8MM.<br />
The major global barrier <strong>to</strong> growth in the PAD market will be the losses of patent<br />
protection <strong>and</strong> market exclusivity on marketed <strong>and</strong> key pipeline drugs during the forecast<br />
period, such as AstraZenecas Cres<strong>to</strong>r (rosuvastatin), Sanofis Plavix (clopidogrel), Brilinta,<br />
<strong>and</strong> Xarel<strong>to</strong>.<br />
The overall level of unmet need in the PAD market is high, resulting in a generous amount<br />
of room for new entrants <strong>to</strong> capitalize on. <strong>Global</strong>Data forecasts that once Brilinta <strong>and</strong><br />
Xarel<strong>to</strong>, pipeline pharmacological agents currently in latestage clinical trials for PAD,<br />
navigate their way through the regula<strong>to</strong>ry l<strong>and</strong>scape <strong>and</strong> secure approval for the PAD<br />
indication, they will address some of the unmet needs in this area.<br />
Download Sample copy of this Report at:<br />
http://www.marketresearchreports.biz/sample/sample/511689<br />
Scope<br />
Overview of peripheral artery disease (PAD), including epidemiology, etiology,<br />
pathophysiology, symp<strong>to</strong>ms, diagnosis, <strong>and</strong> treatment guidelines.<br />
Annualized PAD therapeutics market revenue, annual cost of therapy <strong>and</strong> treatment usage<br />
pattern data from 2014 <strong>and</strong> forecast for ten years <strong>to</strong> <strong>2024</strong>.<br />
Key <strong>to</strong>pics covered include strategic competi<strong>to</strong>r assessment, market characterization,<br />
unmet needs, clinical trial mapping <strong>and</strong> implications for the PAD therapeutics market.<br />
Pipeline analysis: comprehensive data split across different phases, emerging novel trends<br />
under development, <strong>and</strong> detailed analysis of latestage pipeline drugs.<br />
<strong>Analysis</strong> of the current <strong>and</strong> future market competition in the global PAD therapeutics<br />
market. Insightful review of the key industry drivers, restraints <strong>and</strong> challenges. Each trend<br />
is independently researched <strong>to</strong> provide qualitative analysis of its implications.<br />
Reasons <strong>to</strong> buy
Change language